SYRS
Income statement / Annual
Last year (2023), Syros Pharmaceuticals, Inc.'s total revenue was $9.94 M,
a decrease of 33.23% from the previous year.
In 2023, Syros Pharmaceuticals, Inc.'s net income was -$164.57 M.
See Syros Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$9.94 M |
$14.88 M |
$23.49 M |
$15.09 M |
$1.98 M |
$2.05 M |
$1.10 M |
$317,000.00 |
$317,000.00 |
$0.00 |
| Cost of Revenue |
$2.25 M
|
$2.97 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.53 M
|
$0.00
|
$602,000.00
|
$0.00
|
| Gross Profit |
$7.68 M
|
$11.91 M
|
$23.49 M
|
$15.09 M
|
$1.98 M
|
$2.05 M
|
-$426,000.00
|
$317,000.00
|
-$285,000.00
|
$0.00
|
| Gross Profit Ratio |
0.77
|
0.8
|
1
|
1
|
1
|
1
|
-0.39
|
1
|
-0.9
|
0
|
| Research and Development Expenses |
$108.15 M
|
$111.94 M
|
$99.87 M
|
$76.07 M
|
$58.25 M
|
$50.18 M
|
$41.90 M
|
$37.82 M
|
$24.41 M
|
$10.92 M
|
| General & Administrative Expenses |
$28.28 M
|
$29.30 M
|
$23.04 M
|
$21.33 M
|
$21.48 M
|
$16.16 M
|
$13.89 M
|
$10.46 M
|
$5.73 M
|
$2.51 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$28.28 M
|
$29.30 M
|
$23.04 M
|
$21.33 M
|
$21.48 M
|
$16.16 M
|
$13.89 M
|
$10.46 M
|
$5.73 M
|
$2.51 M
|
| Other Expenses |
$0.00
|
-$9.51 M
|
$0.00
|
$0.00
|
$2.30 M
|
$2.02 M
|
$676,000.00
|
$220,000.00
|
$2,000.00
|
$4,000.00
|
| Operating Expenses |
$138.92 M
|
$141.24 M
|
$122.91 M
|
$97.39 M
|
$79.72 M
|
$66.35 M
|
$55.79 M
|
$48.28 M
|
$30.14 M
|
$13.44 M
|
| Cost And Expenses |
$138.92 M
|
$141.24 M
|
$122.91 M
|
$97.39 M
|
$79.72 M
|
$66.35 M
|
$55.79 M
|
$48.28 M
|
$30.14 M
|
$13.44 M
|
| Interest Income |
$6.82 M
|
$2.13 M
|
$87,000.00
|
$426,000.00
|
$2.30 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$5.13 M
|
$4.13 M
|
$3.91 M
|
$1.79 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$2.25 M
|
$2.97 M
|
$3.02 M
|
$3.04 M
|
$2.72 M
|
$1.60 M
|
$1.53 M
|
$1.27 M
|
$602,000.00
|
$258,000.00
|
| EBITDA |
-$157.20 M |
-$87.55 M |
-$79.63 M |
-$79.21 M |
-$72.72 M |
-$60.68 M |
-$53.16 M |
-$46.69 M |
-$29.22 M |
-$13.18 M |
| EBITDA Ratio |
-15.82
|
-8.79
|
-4.1
|
-5.22
|
-37.85
|
-30.58
|
-49.67
|
-147.29
|
-92.17
|
0
|
| Operating Income Ratio |
-12.98
|
-9.13
|
-4.23
|
-5.45
|
-39.22
|
-31.36
|
-49.67
|
-151.3
|
-94.07
|
0
|
| Total Other Income/Expenses Net |
-$35.59 M
|
$41.22 M
|
$12.86 M
|
-$1.74 M
|
$2.30 M
|
$2.02 M
|
$676,000.00
|
$220,000.00
|
$2,000.00
|
$4,000.00
|
| Income Before Tax |
-$164.57 M
|
-$94.65 M
|
-$86.56 M
|
-$84.04 M
|
-$75.44 M
|
-$62.28 M
|
-$54.01 M
|
-$47.74 M
|
-$29.82 M
|
-$13.43 M
|
| Income Before Tax Ratio |
-16.56
|
-6.36
|
-3.69
|
-5.57
|
-38.06
|
-30.38
|
-49.06
|
-150.61
|
-94.06
|
0
|
| Income Tax Expense |
$0.00
|
-$45.35 M
|
$3.91 M
|
$1.79 M
|
$2.55 M
|
$2.02 M
|
-$1.53 M
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$164.57 M
|
-$49.30 M
|
-$90.47 M
|
-$85.83 M
|
-$75.44 M
|
-$62.28 M
|
-$54.01 M
|
-$47.74 M
|
-$29.82 M
|
-$13.43 M
|
| Net Income Ratio |
-16.56
|
-3.31
|
-3.85
|
-5.69
|
-38.06
|
-30.38
|
-49.06
|
-150.61
|
-94.06
|
0
|
| EPS |
-5.81 |
-3.9 |
-14.47 |
-18.64 |
-18.76 |
-19.07 |
-21.26 |
-37.6 |
-120.45 |
-54.25 |
| EPS Diluted |
-5.81 |
-3.9 |
-14.47 |
-18.64 |
-18.76 |
-19.07 |
-21.26 |
-37.6 |
-120.45 |
-54.25 |
| Weighted Average Shares Out |
$28.33 M
|
$12.63 M
|
$6.25 M
|
$4.61 M
|
$4.02 M
|
$3.27 M
|
$2.54 M
|
$1.27 M
|
$247,557.00
|
$247,557.00
|
| Weighted Average Shares Out Diluted |
$28.33 M
|
$12.63 M
|
$6.25 M
|
$4.61 M
|
$4.02 M
|
$3.27 M
|
$2.54 M
|
$1.27 M
|
$247,557.00
|
$247,557.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
